1 : Patient Details. 2 : Medical Aid Details. 3 : Practitioner Detail (Practice) 4 : Patient History

Size: px
Start display at page:

Download "1 : Patient Details. 2 : Medical Aid Details. 3 : Practitioner Detail (Practice) 4 : Patient History"

Transcription

1 1 : Patient Details Surname: Firstname: Initials: ID Number: First Diagnosed: Gender: Telephone: CellPhone: Dependant Code: Birth: Postal Address Fax: 2 : Medical Aid Details Principal Member: Membership Number: Medical Aid: Benefit Option: 3 : Practitioner Detail (Practice) Contact Person: Address: Practice Number: Telephone Number: Group Practice: HPCSA Number: Fax Number: Emergency Urgent 4 : Patient History Diagnosis and Criteria for PMB Condition ICD Code: Histology: Primary Site: First Diagnosis PMB Code: Condition: Metastatic Spread To Adjacent Organ Evidence of Distant, Metastatic Spread Irreverible/ Irreparable damage to organ of origin or other vital organ Well demonstrated 5 year survival rate of greater than 10%

2 ICD Code: Primary Site: Second Diagnosis and Criteria for PMB Condition Histology: Second Diagnosis PMB Code: Condition: Metastatic Spread To Adjacent Organ Irreverible/ Irreparable damage to organ of origin or other vital organ Evidence of Distant, Metastatic Spread Demonstrated 5 year survival rate for this cance is greater than 5% 5 : Other Clinical Information Grade: ECOG Scale: AJCC: Disease Stage T: N: M: Stage Other: Metastases: Bone Brain Liver Lung Other: Receptors: Co-Morbid: Treatment History Date Descr Drugs Outcome Comments

3 6 : Treatment Intent and Review Plan Effective Treatment Intent: SAOC Level: Clinical Trial : Hormone Manipulation Radiotheapy Chemotherapy: Other: Hospital Practice No: Hospital Hospital Motivation: Additional Comments: Treatment Review: Practitioner Signature:

4 7 : Radiotherapy Treatment - (RAD) Professional Practice No.: Professional Fees: Technical Practice No.: Technical Fees: Start Date.: Area of Interest: Supporting Items : Duration in Weeks: Dose: Radiotherapy : Prostate Volume: Gleason Grade: PSA: IPSS: Prostate Stage: Hospital : Radiotherapy Comments: Radiotherapy Planning Code Product Name Commencement Week(s) UnitPrice Code Professional Technical Radiation Code Radiotherapy Planning Code Sub : Product Name Commencement Week(s) UnitPrice Code Professional Technical Radiation Code Sub :

5 Product Name Commencement Week(s) UnitPrice Code Professional Technical Isotope Brachy Code Isotope Sub : Product Name Commencement Week(s) UnitPrice Code Professional Technical Supporting Items and Materials Brachy Code Sub : Product Name Commencement Week(s) UnitPrice Code Supporting Items and Materials Sub :

6 8 : Chemotherapy Treatment - (CHEM) Professional Practice No.: Chemo Prov Practice No.: Facility Practice No.: Starting Date.: Height: Weight: Body Surface: Chemotherapy Comments: StartDate s Chemotherapy : Part 1 Cost Cost Port Insertion Hospital: Chemotherapy Service Fees Chemotherapy Service Fees Sub :

7 Chemotherapy Drugs Chemotherapy Drugs Sub : Supporting Drugs, Materials and Fluids Supporting Drugs, Materials and Fluids Sub :

8 StartDate s Chemotherapy : Part 2 Cost Cost Port Insertion Chemotherapy Service Fees Hospital: Chemotherapy Service Fees Sub : Chemotherapy Drugs Chemotherapy Drugs Sub : Supporting Drugs, Materials and Fluids Supporting Drugs, Materials and Fluids Sub :

Evaluation of Cancer Outcomes Barwon South West Registry

Evaluation of Cancer Outcomes Barwon South West Registry Evaluation of Cancer Outcomes Barwon South West Registry Data Request Form Applicant details Applicant name: Position: Email: Project start date: Date: Telephone: Project completion date: Project details

More information

Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer

Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer Gleason score Gleason score 2-4: well differentiated (seldom reported now): Low risk

More information

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Project Overview Ronald C. Chen, MD MPH Introductions Principal Investigator: Ronald C. Chen, MD MPH ACS Staff: Eileen Tonner,

More information

Clinical Management Guideline for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat:

Clinical Management Guideline for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat: Clinical Management Guideline for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PROSTATE CANCER Patient information given at each stage following

More information

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA /2/17 Eileen Tonner, MS

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA /2/17 Eileen Tonner, MS NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA 2017-040 5/2/17 Eileen Tonner, MS Purpose of the Study For patients who have received curative-intent prostate

More information

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors

More information

Standards for Cancer Registries, Volume II: Data Standards and Data Dictionary, Eighth Edition. COC Collect. COC Transmit

Standards for Cancer Registries, Volume II: Data Standards and Data Dictionary, Eighth Edition. COC Collect. COC Transmit 10 Record Type R R NAACCR 20 Patient ID Number R R R Reporting Registry 30 Registry Type NAACCR 35 FIN Coding System S NAACCR 37 Reserved 00 40 Registry ID S R R NAACCR 50 NAACCR Record Version R R NAACCR

More information

The European Board of Urology

The European Board of Urology Page 1 of 15 The European Board of Urology Sub-specialty certification application: Prostate cancer, A - General information A1 - APPLICATION IDENTIFICATION 1a. Application code blank 1b. EBU internal

More information

Oncology Benefit 2018

Oncology Benefit 2018 Oncology Benefit 2018 Who we are LA Health Medical Scheme (referred to as the Scheme ), registration number 1145, is a non-profit organisation, registered with the Council for Medical Schemes. Discovery

More information

METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /

METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin

More information

Oncology Programme 2017

Oncology Programme 2017 Oncology Programme 2017 Your cover for cancer treatment in 2017 Overview This document explains how Discovery Health Medical Scheme the Scheme covers you for cancer treatment on DiscoveryCare s Oncology

More information

Interactive Staging Bee

Interactive Staging Bee Interactive Staging Bee ROBIN BILLET, MA, CTR GA/SC REGIONAL CONFERENCE NOVEMBER 6, 2018? Clinical Staging includes any information obtained about the extent of cancer obtained before initiation of treatment

More information

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work. Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation

More information

The American Society of Diagnostic and Interventional Nephrology. Application for Recertification. Hemodialysis Vascular Access Procedures

The American Society of Diagnostic and Interventional Nephrology. Application for Recertification. Hemodialysis Vascular Access Procedures The American Society of Diagnostic and Interventional Nephrology Application for Recertification Hemodialysis Vascular Access Procedures SPECIAL NOTE: DO NOT SEND PATIENT IDENTIFIERS IN ANY OF THE PAGES

More information

PLEASE COMPLETE THE PRE-APPLICATION SCREENING FORM IN FULL

PLEASE COMPLETE THE PRE-APPLICATION SCREENING FORM IN FULL Page 1 of 11 Page 2 of 11 Page 3 of 11 PLEASE COMPLETE THE PRE-APPLICATION SCREENING FORM IN FULL 1. PERSONAL INFORMATION SURNAME.TITLE FIRST NAMES AGE GENDER.DATE OF BIRTH. STUDENT NUMBER (only applicable

More information

Oncology Programme 2015

Oncology Programme 2015 Oncology Programme 2015 Overview This document explains the University of KwaZulu-Natal Medical Scheme Oncology Programme for 2015 It gives you details about: What you need to do when you are diagnosed

More information

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group

More information

Informed Consent. Clinical Information

Informed Consent. Clinical Information IRB APPROVED MULTI-MEDIA SYSTEMS, INC. Form Revised March 2010 100 Radcliffe Drive, Chestertown, MD 21620 Tel: 866-ILS-1199/410-810-7506 Fax: 410-810-7508 Clinical Case Report (For Collection of Cancerous

More information

Requirements for Abstracted Text

Requirements for Abstracted Text Slide 1 Requirements for Abstracted Text Principles of Abstracting Lesson 3: Purpose of Text Slide 2 Available Text Fields Place of Diagnosis Immunotherapy Chemotherapy Hormone Therapy Other Therapy Radiation

More information

Oncology Programme 2017

Oncology Programme 2017 Oncology Programme 2017 Who we are Remedi Medical Aid Scheme (referred to as 'the Scheme"), registration number 1430, is a non-profit organisation, registered with the Council for Medical Schemes. Discovery

More information

Attending Physician Statement- Cancer or Carcinoma in-situ

Attending Physician Statement- Cancer or Carcinoma in-situ Instruction to doctor: This patient is insured with us against the happening of certain contingent events associated with his health. A claim has been submitted in connection with Cancer or Carcinoma in-situ.

More information

The American Society of Diagnostic and Interventional Nephrology. Application for Recertification. Peritoneal Dialysis Catheters

The American Society of Diagnostic and Interventional Nephrology. Application for Recertification. Peritoneal Dialysis Catheters The American Society of Diagnostic and Interventional Nephrology Application for Recertification Peritoneal Dialysis Catheters SPECIAL NOTE: DO NOT SEND PATIENT IDENTIFIERS IN ANY OF THE PAGES SUBMITTED.

More information

Prostate Cancer in comparison to Radiotherapy alone:

Prostate Cancer in comparison to Radiotherapy alone: Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +

More information

West Midlands Sarcoma Advisory Group

West Midlands Sarcoma Advisory Group West Midlands Sarcoma Advisory Group Guideline for the Initial Investigation and Referral to Specialist Sarcoma Multi Disciplinary Team for Suspected Bone Sarcoma Version History Version Date Brief Summary

More information

A cost analysis of endoscopic ultrasound in the evaluation of esophageal cancer Harewood G C, Wiersema M J

A cost analysis of endoscopic ultrasound in the evaluation of esophageal cancer Harewood G C, Wiersema M J A cost analysis of endoscopic ultrasound in the evaluation of esophageal cancer Harewood G C, Wiersema M J Record Status This is a critical abstract of an economic evaluation that meets the criteria for

More information

Please consider the following information on ZYTIGA (abiraterone acetate). ZYTIGA - Compendia Communication - NCCN LATITUDE and STAMPEDE June 2017

Please consider the following information on ZYTIGA (abiraterone acetate). ZYTIGA - Compendia Communication - NCCN LATITUDE and STAMPEDE June 2017 Page 1 of 2 Janssen Scientific Affairs, LLC 1125 Trenton-Harbourton Road PO Box 200 Titusville, NJ 08560 800.526.7736 tel 609.730.3138 fax June 08, 2017 Joan McClure 275 Commerce Drive #300 Fort Washington,

More information

Breast Cancer with Brain Metastases: the Role and Treatment Consideration of Radiotherapy

Breast Cancer with Brain Metastases: the Role and Treatment Consideration of Radiotherapy Breast Cancer with Brain Metastases: the Role and Treatment Consideration of Radiotherapy Case Number: RT2009-127(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor Purpose:

More information

ERLEADA (apalutamide) oral tablet

ERLEADA (apalutamide) oral tablet ERLEADA (apalutamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

Medication Prior Authorization Form

Medication Prior Authorization Form Policy Number: 1047 Eligard (leuprolide acetate) 7.5mg Eligard (leuprolide acetate) 22.5mg Eligard (leuprolide acetate) 30mg Eligard (leuprolide acetate)45mg Firmagon (degarelix) Lupaneta Pack (leuprolide

More information

PSA is rising: What to do? After curative intended radiotherapy: More local options?

PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung

More information

Survival rates for prostate cancer stage 3

Survival rates for prostate cancer stage 3 Survival rates for prostate cancer stage 3 14-3-2016 Survival rates tell you what portion of people with the same type and stage of cancer are still alive a certain amount of time (usually 5 years) after

More information

NON INFUSIONAL CHEMOTHERAPY. i. Oral chemotherapy - per cycle (every three to four weeks) v. Bolus IVI chemotherapy - per day of administration

NON INFUSIONAL CHEMOTHERAPY. i. Oral chemotherapy - per cycle (every three to four weeks) v. Bolus IVI chemotherapy - per day of administration Tel: +27-21-9494060 Fax: +27-21-9494112 E-mail: leon.gouws@cancercare.co.za CODE DESCRIPTIONS, INTERPRETATION AND GUIDELINES FOR USE BY MEDICAL ONCOLOGISTS (PR 23*), CLINICAL AND RADIATION ONCOLOGISTS

More information

Overview of Radiotherapy for Clinically Localized Prostate Cancer

Overview of Radiotherapy for Clinically Localized Prostate Cancer Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive

More information

Ophthalmologist/Optometrist/Low Vision Clinic Report. 1.1 Title: (Mr/Mrs/Miss, etc) Surname: Full Names:. 1.4 Physical Address:.

Ophthalmologist/Optometrist/Low Vision Clinic Report. 1.1 Title: (Mr/Mrs/Miss, etc) Surname: Full Names:. 1.4 Physical Address:. OPTIMA COLLEGE COMPUTER SKILLS PROGRAMME APPLICATION FORM PLEASE NOTE: Incomplete applications will not be considered. Please ensure that the following are attached: Medical Report Ophthalmologist/Optometrist/Low

More information

NATIONAL QUALITY FORUM

NATIONAL QUALITY FORUM Cancer Endorsement Maintenance Table of Submitted Measures Phase I 0210 1 Proportion receiving chemotherapy in the last 14 days of life Percentage of patients who died from cancer receiving chemotherapy

More information

Hemodialysis Vascular Access Procedures

Hemodialysis Vascular Access Procedures The American Society of Diagnostic and Interventional Nephrology Application for Certification Practice Experience Track Hemodialysis Vascular Access Procedures SPECIAL NOTE: DO NOT SEND PATIENT IDENTIFIERS

More information

PHARMO Database Network

PHARMO Database Network Pros & cons in Oncology studies PHARMO Myrthe Database van Herk-Sukel, Network PhD 1 Disclosure Myrthe van Herk-Sukel is an employee of the PHARMO Institute for Drug Outcomes Research. This independent

More information

Cancer Risk Assessment Questionnaire

Cancer Risk Assessment Questionnaire Information about your health, lifestyle, and family history will help us determine your risk for cancer. If you already have cancer, it can help us determine the chance your cancer was caused by an inherited

More information

TOPIC Presenter Rihab Sidahmed Ibnoaf Arabic perspective of principles of Screening and diagnostics in Ovarian Cancer, Sudan.

TOPIC Presenter Rihab Sidahmed Ibnoaf Arabic perspective of principles of Screening and diagnostics in Ovarian Cancer, Sudan. Arabic perspective of principles of Screening and diagnostics in Ovarian Cancer, Sudan. Ovarian cancer is the seventh most common cancer, and it is the most common cause of mortality from gynecological

More information

11/3/2016. Outcomes Watching It Grow. What will we discuss? GATRA Annual Conference 2016 Lisa Connor, CTR

11/3/2016. Outcomes Watching It Grow. What will we discuss? GATRA Annual Conference 2016 Lisa Connor, CTR Outcomes Watching It Grow GATRA Annual Conference 2016 Lisa Connor, CTR The abstract begins after case finding The abstract is in progress The abstract is complete The abstract is revisited and nurtured

More information

GUIDELINES ON PROSTATE CANCER

GUIDELINES ON PROSTATE CANCER 10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal

More information

Louisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust

Louisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust Louisa Fleure Advanced Prostate Cancer Clinical Nurse Specialist Guys and St Thomas NHS Trust The classification of advanced prostate cancer The incidence of patients presenting with, or developing advanced

More information

The New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process

The New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process The New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process Wednesday, April 29, 2009 at 11 AM Central M. Asa Carter, CTR Manager, Approvals and Standards

More information

2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures

2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures 2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures The table below includes measures directly relevant to oncology providers as well as general

More information

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines SEER EOD and Summary Stage KCR 2018 SPRING TRAINING Overview What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets SEER Summary Stage 2018 Site Specific

More information

Community care of Prostate Cancer. Shaun Costello Southern Cancer Network

Community care of Prostate Cancer. Shaun Costello Southern Cancer Network Community care of Prostate Cancer Shaun Costello Southern Cancer Network Introduction Why is GP follow up of prostate cancer important 4Years In Waikato Faster Cancer Treatment Reporting against the 3

More information

Public Comment Period for Proposed Radiation Oncology Survivorship Care Plan Template

Public Comment Period for Proposed Radiation Oncology Survivorship Care Plan Template Public Comment Period for Proposed Radiation Oncology Survivorship Care Plan Template Purpose The aim of this ASTRO-sponsored Survivorship Care Plan (SCP) template is to formulate a standardized treatment

More information

Metastatic Bone Adenocarcinoma with Positive TTF-1 Tumor Stain with a Lung Mass: the Role and Treatment Consideration of RT

Metastatic Bone Adenocarcinoma with Positive TTF-1 Tumor Stain with a Lung Mass: the Role and Treatment Consideration of RT Metastatic Bone Adenocarcinoma with Positive TTF-1 Tumor Stain with a Lung Mass: the Role and Treatment Consideration of RT Case Number: RT2009-74(M) Potential Audiences: Intent Doctor, Oncology Special

More information

Patients who receive image or palpation-guided needle biopsy (core or FNA) for the diagnosis of breast cancer.

Patients who receive image or palpation-guided needle biopsy (core or FNA) for the diagnosis of breast cancer. Description Measure 0221: Needle biopsy to establish diagnosis of cancer precedes surgical excision/resection (Commission on Cancer, American College of Surgeons) Percentage of patients presenting with

More information

How to Manage Esophagus Cancer Patients with ct3n0m0, stage III Disease?

How to Manage Esophagus Cancer Patients with ct3n0m0, stage III Disease? How to Manage Esophagus Cancer Patients with ct3n0m0, stage III Disease? Case Number: RT2009-05(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor Purpose: to present a case

More information

Troubleshooting Audio

Troubleshooting Audio Welcome! Audio for this event is available via ReadyTalk Internet Streaming. No telephone line is required. Computer speakers or headphones are necessary to listen to streaming audio. Limited dial-in lines

More information

If so 1) give details, 2) include what feedback you received and 3) how you have responded to this.

If so 1) give details, 2) include what feedback you received and 3) how you have responded to this. APPLICATION FOR PROFESSIONAL PROGRAMME IN COUNSELLING PSYCHOLOGY 2019 intake. Surname: Age on 13 August 2018: First names: Preferred name (to be called): Date of Birth: Postal Address: Paste your photo

More information

What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).

What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). It is a very common cancer in men; some cancers grow very slowly,

More information

CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I

CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I Changes and Clarifications 16 th Edition April 15, 2016 Quick Look- Updates to Volume

More information

Chronic Benefit Application Form Cardiovascular Disease and Diabetes

Chronic Benefit Application Form Cardiovascular Disease and Diabetes Chronic Benefit Application Form Cardiovascular Disease and Diabetes 19 West Street, Houghton, South Africa, 2198 Postnet Suite 411, Private Bag X1, Melrose Arch, 2076 Tel: +27 (11) 715 3000 Fax: +27 (11)

More information

January Abiraterone pre-docetaxel for patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer

January Abiraterone pre-docetaxel for patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone pre-docetaxel for asymptomatic/minimally symptomatic metastatic castration resistant prostate cancer Abiraterone pre-docetaxel for patients with asymptomatic

More information

The Selenium and Vitamin E Prevention Trial

The Selenium and Vitamin E Prevention Trial The largest-ever-prostate cancer prevention trial is now underway. The study will include a total of 32,400 men and is sponsored by the National Cancer Institute and a network of researchers known as the

More information

National Oncologic PET Registry (NOPR) F-18 Fluoride PET Case Report Forms

National Oncologic PET Registry (NOPR) F-18 Fluoride PET Case Report Forms Form (NOPR) F-18 Fluoride PET Case Report Forms Version Date Patient Information Sheet 06/17/10 (Spanish translation available at: http://www.cancerpetregistry.org/pdf/patient_info_spanish.pdf) Interpreting

More information

Rare Urological Cancers Urological Cancers SSCRG

Rare Urological Cancers Urological Cancers SSCRG Rare Urological Cancers Urological Cancers SSCRG Public Health England South West Knowledge & Intelligence Team 1 Introduction Rare urological cancers are defined here as cancer of the penis, testes, ureter

More information

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #10: NCRA /13/17 Eileen Tonner, MS

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #10: NCRA /13/17 Eileen Tonner, MS NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #10: NCRA 2017-063 6/13/17 Eileen Tonner, MS Study Progress as of 6/13 Number of patients submitted as eligible: 2449 Number

More information

Louisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust

Louisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust Louisa Fleure Advanced Prostate Cancer Clinical Nurse Specialist Guys and St Thomas NHS Trust The classification of advanced prostate cancer The incidence of patients presenting with, or developing advanced

More information

OPTIMA COLLEGE CONTACT CENTRE SUPPORT APPLICATION FORM

OPTIMA COLLEGE CONTACT CENTRE SUPPORT APPLICATION FORM OPTIMA COLLEGE CONTACT CENTRE SUPPORT APPLICATION FORM LEARNING PROGRAMME APPLIED FOR: A: SKILLS PROGRAMME (2 MONTHS) OR B: LEARNERSHIP PROGRAMME (12 MONTHS) PLEASE NOTE: Incomplete applications will not

More information

Illawarra Cancer Care Centre

Illawarra Cancer Care Centre The Audience Who? No apologies! Radiation Oncologists State of Mind Our business Our business is medical Our records are medical records Our information system is electronic medical record Primacy of our

More information

Integration of hospital based breast cancer data and population based data at the Greater Poland Cancer Centre

Integration of hospital based breast cancer data and population based data at the Greater Poland Cancer Centre Integration of hospital based breast cancer data and population based data at the Greater Poland Cancer Centre Maciej Trojanowski Director of the Greater Poland Cancer Registry Department of Cancer Prevention

More information

Enterprise Interest None

Enterprise Interest None Enterprise Interest None Cervical Cancer -Management of late stages ESP meeting Bilbao Spain 2018 Dr Mary McCormack PhD FRCR Consultant Clinical Oncologist University College Hospital London On behalf

More information

Single Technology Appraisal (STA)

Single Technology Appraisal (STA) Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response

More information

Case Number: RT (M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor

Case Number: RT (M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor Squamous Cell Carcinoma with Isolated Upper Mediastinum Nodal Metastasis with Unknown Primary: the Role and Treatment Consideration of RT with Chemotherapy Case Number: RT2009-82(M) Potential Audiences:

More information

SYNOPSIS PROTOCOL N UC-0107/1602

SYNOPSIS PROTOCOL N UC-0107/1602 SYNOPSIS PROTOCOL N UC-0107/1602 A) TRIAL IDENTIFICATION SPONSOR PROTOCOL CODE NUMBER: UC-0107/1602 VERSION (NR & DATE): 0.1, MARCH 2016 TRIAL TITLE: Extracranial Stereotactic Body Radiation Therapy (SBRT)

More information

expectancy Cancer spread to bones life expectancy

expectancy Cancer spread to bones life expectancy Cancer spread to bones life expectancy The Borg System is 100 % Cancer spread to bones life expectancy Sep 27, 2016. About 80 percent of the time prostate cancer cells metastasize, or spread, they will

More information

Definition Prostate cancer

Definition Prostate cancer Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation

More information

NCI/Local Protocol #: RTOG-0521/RTOG NCI Protocol Version Date: December 22, 2014 (Broadcast date: 2/2/2015)

NCI/Local Protocol #: RTOG-0521/RTOG NCI Protocol Version Date: December 22, 2014 (Broadcast date: 2/2/2015) For Protocol Amendment 7of RTOG 0521, A Phase III Protocol of Androgen Suppression (As) And 3DCRT/IMRT Vs. As And 3DCRT/IMRT Followed By Chemotherapy With Docetaxel And Prednisone For Localized, High-Risk

More information

Parisa Mirzadehgan, MPH, CCRP

Parisa Mirzadehgan, MPH, CCRP Parisa Mirzadehgan, MPH, CCRP Approved therapy for a newly diagnosed GBM patient includes surgical resection radiation & temozolomide Upon recurrence there are few approved options surgical implantation

More information

RADIOTHERAPY DEPARTMENT

RADIOTHERAPY DEPARTMENT EXPERIENCES OF CLINICAL AUDIT IN A FINNISH RADIOTHERAPY DEPARTMENT Simo Hyödynmaa and Tuija Wigren Department of Radiation Therapy, Tampere University Hospital, Tampere, FINLAND PIRKANMAA HOSPITAL DISTRICT

More information

COMETRIQ (cabozantinib) oral capsule

COMETRIQ (cabozantinib) oral capsule COMETRIQ (cabozantinib) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Cancer Endorsement Maintenance 2011-Maintenance Measures

Cancer Endorsement Maintenance 2011-Maintenance Measures Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212

More information

C o n t e n t s. 2 Introduction. 3 Personal information. 4 Your medical history. 5 PSA results. 7 Healthcare appointments

C o n t e n t s. 2 Introduction. 3 Personal information. 4 Your medical history. 5 PSA results. 7 Healthcare appointments C o n t e n t s 2 Introduction 3 Personal information 4 Your medical history 5 PSA results 7 Healthcare appointments 9 Diagnostic investigations and test results This booklet has been produced jointly

More information

Part VIII Entering Information Into the Urology Report Form

Part VIII Entering Information Into the Urology Report Form North Carolina Central Cancer Registry Instructions and Reporting Requirements Module 8 Electronic Reporting For Urology Physician Practices May 2013 North Carolina Central Cancer Registry State Center

More information

Bone Metastases Radiation Therapy Physician Worksheet Pages 2-5. Brain Metastases Radiation Therapy Physician Worksheet Pages 6-9

Bone Metastases Radiation Therapy Physician Worksheet Pages 2-5. Brain Metastases Radiation Therapy Physician Worksheet Pages 6-9 evicore Healthcare needs to collect sufficient clinical history and treatment plan information relevant to a request for radiation therapy treatment to establish the medical necessity of the service. evicore

More information

Rule out prostate cancer icd 10

Rule out prostate cancer icd 10 Rule out prostate cancer icd 10 The Borg System is 100 % Rule out prostate cancer icd 10 Rule out metastatic disease icd 10 Icd 10 code rule out cancer -- For your pride and a means of making. Which you

More information

18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan

18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan An update for GPs on modern radiation therapy & hormones for prostate cancer A/Prof Jeremy Millar Director Radiation Oncology, Alfred Health Clinical lead Prostate Cancer Outcomes Registry, Monash University

More information

Oncologic Emergencies: When to call the Radiation Oncologist

Oncologic Emergencies: When to call the Radiation Oncologist Oncologic Emergencies: When to call the Radiation Oncologist Dr. Shrinivas Rathod Radiation Oncologist Radiation Oncology Program CancerCare Manitoba and University of Manitoba Disclosures Speaker s name:

More information

PCSANM 2015 Seminar. Basic Knowledge: Test for Prostate Cancer. Jerry Cross. 15 item quiz, no grades given

PCSANM 2015 Seminar. Basic Knowledge: Test for Prostate Cancer. Jerry Cross. 15 item quiz, no grades given Basic Knowledge: Test for Prostate Cancer Jerry Cross 15 item quiz, no grades given Basic Knowledge: Test for Prostate Cancer From http://prostatesnatchers.blogspot.com/ January 27, 2015 BY MARK SCHOLZ,

More information

North Shore Youth Eating Disorders Program NEW CLIENT REFERRAL

North Shore Youth Eating Disorders Program NEW CLIENT REFERRAL North Shore Youth Eating Disorders Program NEW CLIENT REFERRAL The North Shore Youth Eating Disorders Program (NSYEDP) is a multidisciplinary team consisting of a medical professional, dietitian, and counsellor.

More information

17/07/2014. Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom

17/07/2014. Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom My Biases Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom I am a member of the specialist group of the Prostate

More information

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy. History and Physical Case Scenario 1 45 year old white male presents with complaints of nausea, weight loss, and back pain. A CT of the chest, abdomen and pelvis was done on 12/8/12 that revealed a 12

More information

Recruiting Active; not recruiting Completed Suspended Terminated. The biological sex of the patient. Female Unknown

Recruiting Active; not recruiting Completed Suspended Terminated. The biological sex of the patient. Female Unknown Clinical Data Form Kidney Carcinoma Clinical Trial Sequencing Project Page 1 The Clinical Data Form (CDF) should be completed for every case. This form can be completed at the time the samples are submitted,

More information

Survival outcomes for men in rural and remote NSW. Trend in prostate cancer incidence and mortality rates in Australia. The prostate cancer conundrum

Survival outcomes for men in rural and remote NSW. Trend in prostate cancer incidence and mortality rates in Australia. The prostate cancer conundrum 7/8/20 7/8/20 Using PROMS to better understand prostate cancer outcomes: The NSW Prostate Cancer Care and Outcomes Study David Smith Research Fellow Cancer Research Division Monash Uni, 26 th June 20 Survival

More information

W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability

W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability Background: The key issue is to investigate whether some of the data

More information

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA) Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology

More information

Australian Organisation Launches Large International Clinical Trials in Prostate Cancer

Australian Organisation Launches Large International Clinical Trials in Prostate Cancer Australian Organisation Launches Large International Clinical Trials in Prostate Cancer Media Release Sydney 8 April, 2014: The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials

More information

Cancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS)

Cancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS) MEASURE SPECIFICATIOS Cancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS) Introduction The Commission on Cancer s (CoC) ational Cancer Data Base (CDB) staff has undertaken

More information

Causation Issues. Delay in Diagnosis of Cancer Cases. Prof Pat Price Imperial College London

Causation Issues. Delay in Diagnosis of Cancer Cases. Prof Pat Price Imperial College London Causation Issues Delay in Diagnosis of Cancer Cases Prof Pat Price Imperial College London office@patprice.co.uk www.patprice.co.uk Faculty of Advocates Annual conference 18 th June 2018 EVIDENCE BASED

More information

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,

More information

MEASURE SPECIFICATIONS

MEASURE SPECIFICATIONS QOPI REPTING REGISTRY (QCDR) 2018 QOPI 5 QOPI 11 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Combination chemotherapy

More information

Medicare & Dual Options. 1. Every page of the EMR document must include: a. Member Name b. Patient Identifiers (i.e. Date of Birth) c.

Medicare & Dual Options. 1. Every page of the EMR document must include: a. Member Name b. Patient Identifiers (i.e. Date of Birth) c. Medicare & SUBMITTING PROGRESS NOTES OR EMR You may use your own progress notes or Electronic Medical Record (EMR) to document the annual comprehensive examination. The EMR must include the elements indicated

More information

MEASURE SPECIFICATIONS

MEASURE SPECIFICATIONS QOPI REPTING REGISTRY (QCDR) 2018 QOPI5 Title Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Description Percentage

More information

Online Form. Welcome to the Integrated Research Application System. IRAS Project Filter

Online Form. Welcome to the Integrated Research Application System. IRAS Project Filter Welcome to the Integrated Research Application System IRAS Project Filter The integrated dataset required for your project will be created from the answers you give to the following questions. The system

More information

Stage 4 bone cancer life expectancy

Stage 4 bone cancer life expectancy Stage 4 bone cancer life expectancy The Borg System is 100 % Stage 4 bone cancer life expectancy Stage 4 bone cancer survival rate (Prognosis). Is it possible to cure stage 4 bone cancer? What factors

More information

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA

More information